Mass Tort Settlement Tracker

$10.5 billion to $12.5 billion paid over 13 years to public water systems for PFAS contamination, per the official settlement FAQ. Final approval entered by Judge Gergel (fairness hearing February 2, 2024). Compensates water utilities, not individuals.

$1.185 billion settlement resolving claims of roughly 14,000 public water systems. Final approval entered following the December 14, 2023 fairness hearing.

$750 million settlement; final approval order entered November 2024 (ECF 6406).

$316.5 million total ($312.5M settlement amount + $4M notice/administration); agreement signed May 20, 2024, final approval entered November 22, 2024.

The official administrator identifies four finally approved settlements for eligible public water systems. These contamination settlements do not compensate individual injury claims. A review of the public MDL orders and administrator website on September 14, 2026 did not identify a global personal-injury settlement or an official individual payout schedule.

CMO 56 established a qualified settlement fund for eligible settling claimants. CMO 55 provides settlement conferences and mediation for defined unresolved claimants beginning on or about January 4, 2027. The orders reviewed do not publish a total settlement amount or a uniform individual payment.

The Arizona public MDL orders reviewed on September 14, 2026 did not identify a global settlement program. The posted order collection reviewed ends with CMO 46 in March 2026, so it cannot establish the absence of later private resolutions.

DOJ’s August 10, 2026 totals describe aggregate CLJA settlement activity. EO diagnosis and exposure tiers range from $100,000 to $450,000, with a further $100,000 for qualifying deaths. Individual eligibility and payment depend on the applicable program and completed documents; aggregate totals are not average awards.

Court orders confirm a confidential settlement program for eligible Depo-Provera claims, with BrownGreer appointed administrator on August 5, 2026. CMO 14 identifies November 30, 2026 as the registration deadline. The public orders reviewed September 14 do not disclose an aggregate fund or individual payout grid. This is a private agreement, not a class settlement requiring a fairness hearing. Nonparticipating and ineligible claims continue under court procedures.

The court documents reviewed on September 14, 2026, including CMO 24 and CMO 17, do not establish a global settlement or payout schedule. CMO 17 authorizes settlement coordination and expressly warns against inferring timing or likelihood from the appointment.

J&J’s July 27, 2026 SEC-filed announcement requires participation representing at least 95% of remaining ovarian-talc claims and other conditions. It calls for an initial payment of no more than $3 billion in 2027, with no additional payments due before 2028. This describes company funding, not an individual claimant payment date. The records reviewed on September 14 do not establish satisfaction of all conditions.

The Eastern District of Pennsylvania public MDL orders reviewed September 14, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The scheduled Rule 702 hearing concerns expert evidence, not settlement eligibility or an individual award.

The Northern District of Georgia public MDL page and posted orders reviewed on September 14, 2026 did not identify a global settlement program. The Rickard verdict resolves the trial issues in that individual case; it does not determine the outcome or value of other claims.

CMO 24 identifies a confidential Master Settlement Agreement executed September 3, 2025 for certain individual claims. The special master reviews qualification, eligibility and opt-out information. Public orders checked September 14, 2026 do not disclose a payout grid, settlement total or average individual award. A pending MDL action does not by itself establish settlement eligibility.

The proposed King v. Monsanto class settlement provides up to $7.25 billion, subject to final approval. The fairness hearing was held September 14, 2026; the administrator says the court will now decide whether to approve the settlement and that the timing is unknown. June 4 objection and opt-out deadlines have passed.

The federal court page and court-linked MDL Centrality materials reviewed September 14, 2026 do not identify a global personal-injury settlement program or official individual payout schedule. Outcomes in government cases or individual proceedings do not determine what another claimant will receive.

The Northern District of Ohio public MDL order index and bellwether protocol reviewed September 14, 2026 do not announce a dental-injury settlement program or individual payout schedule. Separate Suboxone antitrust and opioid-enforcement settlements do not resolve these dental-injury claims.